Abstract
Drug prescription in children intended to diagnose and treat pathologies in the anterior segment poses a big challenge to the eye doctors as it requires a broad knowledge thereof at the time of prescribing and administering effective treatments while ensuring a minimal risk of adverse effects. This work aims to provide a reference of some points to take into account when prescribing topical eye drugs, either for diagnosing or treating eye pathologies in the anterior segments in children below 12 years old. To do so, a document search and review was conducted in among different scholarly and scientific databases such as SciELO and PubMed for the term 1993-2019. The Results section describes important aspects such as pharmacokinetics and physiopathology to consider when it comes to diagnose or treat those eye pathologies most frequently found among children, based on recommendations by previous authors. Finally, a conclusion is drawn that when prescribing eye drugs to children is quite important to determine the right doses in order to prevent toxic effects by considering the physiopathological and pharmacokinetic aspects involved. This work shows an opportunity to encourage more research in Colombia on topical eye drugs and uncovers the need to provide this kind of antibiotics for children below 6 months old and anti-allergic and anti-inflammatory drugs for children below 2 years old in our countryReferences
Medrano SM, Mayorga C. MT. Caracterización de la morbilidad visual y ocular de la población atendida en Colombia, según los reportes de los RIPS, 2009 y 2010. Cienc Tecnol para la Salud Vis y Ocul. 2015;13(1):45-64. DOI: 10.19052/sv.2870
Medrano SM, Duarte A. Caracterización de la morbilidad visual y ocular de la población atendida en la región de la Orinoquía y la Amazonía, según los reportes de los RIPS, 2009 y 2010. Cienc Tecnol para la Salud Vis y Ocul. 2015;13(1):113-122. DOI: 10.19052/sv.3376
Márquez MM, Cáceres MC. Caracterización de la salud visual y ocular en niños de un centro de desarrollo infantil de un barrio marginal de Pereira, Colombia. UstaSalud. 2018;16(1):17-27. DOI: 10.15332/us.v16i0.2016
Batchelor HK, Marriott JF. Formulations for children: Problems and solutions. Br J Clin Pharmacol. 2015;79(3):405-18. DOI: 10.1111/bcp.12268
Farkouh A, Frigo P, Czejka M. Systemic side effects of eye drops: A pharmacokinetic perspective. Clin Ophthalmol. 2016;10:2433-41. DOI: 10.2147/OPTH.S118409
Vaajanen A, Vapaatalo H. A Single drop in the eye-effects on the whole body? Open Ophthalmol J. 2017;11:305-14. DOI:10.2174/1874364101711010305
Izazola-Conde C, Zamora-de la Cruz D, Tenorio-Guajardo G. Ocular and systemic adverse effects of ophthalmic and non ophthalmic medications. Proc West Pharmacol Soc. 2011;54:69-72
Zafra Anta MA, Zafra Anta L, García-Vao Bel CM, Rivero Martín MJ, Toledano Fernández N. Cuadro confusional agudo tras uso de colirio ciclopléjico en una niña de 6 años de edad. Acta Pediatr Esp. 2010;68(2):88-90. https://pesquisa.bvsalud.org/portal/resource/pt/ibc-85920
Boots I, Sukhai RN, Klein RH, Holl RA, Wit JM, Cohen AF, et al. Stimulation programs for pediatric drug research-Do children really benefit? Eur J Pediatr. 2007;166(8):849-55. DOI: 10.1007/s00431-006-0381-z
Molina N. Aspectos éticos en la investigación con niños. Cienc Tecnol Salud Vis y Ocul. 2018;16(1):75-87. DOI: 10.19052/sv.4348
Dave VS, Bhansali SG. Pharmacokinetics and pharmacodynamics of ocular drugs. In: Pathak Y, Sutariya V y Hirani A, editores. Nano-biomaterials for ophthalmic drug delivery. Zürich: Springer International Publishing; 2016. p. 111-30. DOI: 10.1007/978-3-319-29346-2_6
Agrahari V, Mandal A, Agrahari V, Trinh HM, Joseph M, Ray A, et al. A comprehensive insight on ocular pharmacokinetics. Drug Deliv Transl Res. 2016;6(6):735-54. DOI: 10.1007/s13346-016-0339-2
Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev. 2006;58(11):1131-5. DOI: 10.1016/j.addr.2006.07.027
Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: An overview. World J Pharmacol. 2013;2(2):47-64. DOI: 10.5497/wjp.v2.i2.47
Ku LC, Smith PB. Dosing in neonates: special considerations in physiology and trial design. Pediatr Res. 2015;77(1-1):2-9. DOI: 10.1038/pr.2014.143
Baak JP, Mutter GL, Robboy S, Van Diest PJ, Uyterlinde AM, Ørbo A, et al. In endometrial hyperplasias, the molecular-genetics and morphometry-based EIN classification more accurately predicts cancer-progression than the WHO94. Cancer. 2005;103(11):2304-12. DOI: 10.1002/cncr.21058
Lu H, Rosenbaum S. Developmental pharmacokinetics in pediatric populations. J Pediatr Pharmacol Ther. 2014;19(4):262-76. DOI: 10.5863/1551-6776-19.4.262
Baños JE, March M. Farmacología ocular. Barcelona: Edicions Universitat Politècnica de Catalunya; 2002. Disponible en http://hdl.handle.net/2099.3/36690
Bartlett JD, Jaanus, SD. Clinical ocular pharmacology. 2.ª ed. Oxford: Elsevier; 2008
American Optometric Association. Comprehensive pediatric eye and vision examination.. St. Louis: AOA; 2017. Disponible en https://www.aoa.org/optometrists/tools-and-resources/clinical-care-publications/clinical-practice-guidelines
Wallace DK, Morse CL, Melia M, Sprunger DT, Repka MX, Lee KA, et al. Pediatric Eye Evaluations Preferred Practice Pattern®: I. Vision Screening in the Primary Care and Community Setting; II. Comprehensive Ophthalmic Examination. Ophthalmology. 2018;125(1):184-P227. DOI: 10.1016/j.ophtha.2017.09.032
Baiza-durán LM, González JR, Dios J De, Hau Q. Estudio clínico comparativo de la eficacia de dos concentraciones de ciclopentolato tópico oftálmico en población pediátrica. Rev Mex Oftalmol. 2007;81(5):250-2. Disponible en https://www.medigraphic.com/pdfs/revmexoft/rmo-2007/rmo075c.pdf
Jiménez-Jiménez FJ, Alonso-Navarro H, Fernández-Díaz A, Adeva-Bartolomé MT, Ruiz-Ezquerro JJ, Martín-Prieto M. Efectos neurotóxicos inducidos por administración tópica de ciclopléjicos. Caso clínico y revisión de la bibliografía. Rev Neurol. 2006;43(10):603-9
Rajeev A, Gupta G, Adhikari K, Yadav A, Sathyamoorthy M. Neurotoxic Effects of Topical Cyclopentolate. Med J Armed Forces India. 2010;66(3):288-9. DOI: 10.1016/S0377-1237(10)80069-3
Ashena Z, Webber S. Acquired lateral upper lid entropion in a child treated with Botulinum toxin. Eye (Lond). 2012;26(10):1390-1. DOI: 10.1038/eye.2012.143
Patel AJ, Simon JW, Hodgetts DJ. Cycloplegic and mydriatic agents for routine ophthalmologic examination: A survey of pediatric ophthalmologists. J AAPOS. 2004;8(3):274-7. DOI: 10.1016/j.jaapos.2004.01.004
Comité de Medicamentos de la Asociación Española de Pediatría. Pediamécum; 2002. Disponible en https://www.aeped.es/comite-medicamentos/pediamecum/ciclopentolato
Mühlhausen G, González A, editores. Guía de práctica clínica: unidad de Neonatología. Santiago de Chile: Hospital de San José; 2016. http://www.manuelosses.cl/BNN/gpc/Manual%20Neo_H.SnJose_2016.pdf
Bonci F, Lupelli L. Retinoscopy in infancy : cycloplegic vs non cycloplegic retinoscopy. ResearchGate. 2012;49-53. Disponible en: https://www.researchgate.net/publication/264129301_Retinoscopy_in_Infancy_cycloplegic_vs_non_cycloplegic_retinoscopy
Scott AL. Atropine. Encycl Toxicol 3.ª ed. 2014;1:339-41
Brenner GM, Stevens CW. Farmacologia ocular. 5.ª ed. Barcelona: Elsevier; 2018
Kyei S, Nketsiah AA, Asiedu K, Awuah A, Owusu-Ansah A. Onset and duration of cycloplegic action of 1% cyclopentolate 1% tropicamide combination. Afr Health Sci. 2017;17(3):923-32. DOI: 10.4314/ahs.v17i3.36
Pineles SL, Kraker RT, VanderVeen DK, Hutchinson AK, Galvin JA, Wilson LB, et al. Atropine for the Prevention of Myopia Progression in Children: A Report by the American Academy of Ophthalmology. Ophthalmology. 2017;124(12):1857-66. DOI: 10.1016/j.ophtha.2017.05.032
Food and Drugs Administration. Isopt Atropine 1 % for topical ophthalmic use. 2016; 4-9. Disponible en https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208151lbl.pdf
Princelle A, Hue V, Pruvost I, Potey C, Dubos F, Martinot A. Effets systémiques des collyres mydriatiques atropiniques chez deux enfants [Systemic adverse effects of topical ocular instillation of atropine in two children]. Arch Pediatr. 2013;20(4):391-4. DOI: 10.1016/j.arcped.2013.01.012
Wakayama A, Nishina S, Miki A, Utsumi T, Sugasawa J, Hayashi T, Sato M, Kimura A, Fujikado T. Incidence of side effects of topical atropine sulfate and cyclopentolate hydrochloride for cycloplegia in Japanese children: a multicenter study. Jpn J Ophthalmol. 2018 Sep;62(5):531-536. DOI: 10.1007/s10384-018-0612-7
Frazier M, Jaanus SD. Cycloplegics. En: Bartlett J, Jaanus S, Fiscella R. Holdeman N, Prokopich L, editores. Clinical Ocular Pharmacology. 5.ª ed. Butterworth-Heinemann: Elsevier; 2008. p. 125-38. DOI: 10.1016/B978-0-7506-7576-5.50014-8
Fortinguerra F, Clavenna A, Bonati M. Ocular medicines in children: The regulatory situation related to clinical research. BMC Pediatr. 2012;12(1):8. DOI: 10.1186/1471-2431-12-8
Peréz M, Luque R, Santolaya R, Tornero O, Requena T. Estabilidad y esterilidad de un colirio de Fenilefrina al 2,5 %. Farm Hosp. 1999;5:48-52
British National Formulary for Children The essential resource for clinical use of medicines in children. 2011-2012; capítulo 11. Disponible en: https://www.sbp.com.br/fileadmin/user_upload/pdfs/british_national_formulary_for_children_2011-2012.pdf
Garzón J. Farmacoterapia Ocular: aplicaciones clinicas de La Farmacologia ocular en el Segmento Anterior. Bogotá: Universidad de La Salle; 2011
Bremond-Gignac D, Chiambaretta F, Milazzo S. A European Perspective on Topical Ophthalmic Antibiotics: Current and Evolving Options. Ophthalmol Eye Dis. 2011;3:29-43. DOI: 10.4137/OED.S4866
Weiss A, Brinser JH, Nazar-Stewart V. Acute conjunctivitis in childhood. J Pediatr. 1993;122(1):104. DOI: 10.1016/s0022-3476(05)83479-1
Chawla R, Kellner JD, Astle WF. Acute infectious conjunctivitis in childhood. Paediatr Child Health. 2001;6(6):32935. DOI: 10.1093/pch/6.6.329
Orden B, Martínez R, Millán R. Conjuntivitis bacteriana: Patógenos más prevalentes y sensibilidad antibiótica. An Pediatr. 2004;61(1):32-6. DOI: 10.1016/S1695-4033(04)78350-2
Rietveld RP, ter Riet G, Bindels PJ, Sloos JH, van Weert HC. Predicting bacterial cause in infectious conjunctivitis: Cohort study on informativeness of combinations of signs and symptoms. BMJ. 2004;329(7459):206-10. DOI: 10.1136/bmj.38128.631319.AE
Fano Y. Complicaciones de la Blefaritis. Presentación de caso. Revista Habanera de Ciencias Médicas. 2016;15(1):829. http://scielo.sld.cu/pdf/rhcm/v15n1/rhcm10116.pdf
Rammohan ME, G. Blefaritis. En: StatPearls. Treasure Island: StatPearls Publishing;2020. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK459305/
Bragg KJ, Le PH, Le JK. Hordeolum. En: StatPearls. Treasure Island: StatPearls Publishing; 2020. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK441985/
Piera M. Pequeñas afecciones y urgencias oftalmològicas: Actuación inmediata. Revista Farmacia Porfesional. 2001;15(4):74-9. Disponible en: https://www.elsevier.es/es-revista-farmacia-profesional-3-articulo-pequenas-afecciones-urgencias-oftalmologicas-actuacion-12003986
Centro Nacional de Excelencia y Salud. Diagnóstico y manejo del orzuelo y chalazión. ciudad de México:_Cenetec; 2009. Disponible en: http://www.cenetec.salud.gob.mx/descargas/gpc/CatalogoMaestro/316_GPC_ORZUELO_Y_CHALAZION/chalazion_EVR_CENETEC.pdf
Barberá E, Vázquez F. Tratamientos tópicos oculares: revisión. Información Terapéutica del sistema Nacional de Salud. 2009;33(3):80-7
Melton R, Thomas R. Clinical Guide to Ophthalmic drugs. Review of Optometry. 2016;(supl.): 2-51. https://www.reviewofoptometry.com/CMSDocuments/2016/5/dg0516i.pdf
Cobos-Trigueros N, Ateka O, Pitart C, Vila J. Macrólidos y cetólidos [Macrolides and ketolides]. Enferm Infecc Microbiol Clin. 2009;27(7):412-8. Spanish. DOI: 10.1016/j.eimc.2009.06.002
Newcomb B, Scott CL. Pediatric use of ophthalmic drugs. Optom. J Am Optom Assoc. 2008;75(9):542
Vives EA, Ventriglia MV, Medvedovsky D, Rothlin R. Quimioterápicos inhibidores de la síntesis de ácido tetrahidrofólico. Farmacol II; 2004. Disponible en: https://farmacomedia.files.wordpress.com/2010/05/quimioterapicos-inhibidores-de-la-sintesis-de-acido-tetrahidrofolico.pdf
Arés Álvarez F, Martínez de la Ossa Sáenz-López R, Alfayate Miguélez S. Quinolonas en Pediatría. Rev Pediatr Aten Primaria. 2017; 19(74):e83-e92. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1139-76322017000200018&lng=es
Garzón J. Conjuntivitis alérgicas: diagnóstico y tratamiento. Bogotá: Unisalle; 2015
Balderrávano L, Guzmán CR, Téllez AGA, Ortega JA, Bosch V, Garza R. Alergia ocular en el paciente pediátrico. Pediátricas. 2015;24(2):54-67
Ono SJ, Abelson MB. Allergic conjunctivitis: Update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol. 2005;115(1):118-22. DOI: 10.1016/j.jaci.2004.10.042
Escobar MF, Cardona E. Alergia ocular: un reto diagnóstico. Iatreia. 2007;20(4):362-78
Fontenla JR, Grau M, Díaz P, Váquez X, Pita D. Una conjuntivitis alérgica. Med Integral. 2002;40(9):386-93
Ghiglioni DG, Bruschi G, Gandini S, Osnaghi S, Peroni D, Marchisio P. Vitamin D serum levels in children with vernal keratoconjunctivitis and disease control. Int J Immunopathol Pharmacol. 2019;33. DOI: 10.1177/2058738419833468
Zicari AM, Capata G, Nebbioso M, De Castro G, Midulla F, Leonardi L, et al. Vernal Keratoconjunctivitis: an update focused on clinical grading system. Ital J Pediatr. 2019;45(1):1-6. DOI: 10.1186/s13052-019-0656-4
Vichyanond P, Pacharn P, Pleyer U, Leonardi A. Vernal keratoconjunctivitis: A severe allergic eye disease with remodeling changes. Pediatr Allergy Immunol. 2014;25(4):314-22. DOI: 10.1111/pai.12197
Bonini S, Sacchetti M, Mantelli F, Lambiase A. Clinical grading of vernal keratoconjunctivitis. Curr Opin Allergy Clin Immunol. 2007;7(5):436-41. DOI: 10.1097/ACI.0b013e3282efb726
Chen JJ, Applebaum DS, Sun GS, Pflugfelder SC. Atopic keratoconjunctivitis: A review. J Am Acad Dermatol. 2014;70(3):569-75. DOI: 10.1016/j.jaad.2013.10.036
Nivenius E, Montan PG, Chryssanthou E, Jung K, Van Hage-Hamsten M, Van Der Ploeg I. No apparent association between periocular and ocular microcolonization and the degree of inflammation in patients with atopic keratoconjunctivitis. Clin Exp Allergy. 2004;34(5):725-30. DOI: 10.1111/j.1365-2222.2004.1950.x
Leonardi A, Doan S, Fauquert JL, Bozkurt B, Allegri P, Marmouz F, et al. Diagnostic tools in ocular allergy. Allergy. 2017;72(10):1485-98. DOI: 10.1111/all.13178
Ridolo E, Kihlgren P, Pellicelli I, Nizi MC, Pucciarini F, Incorvaia C. Atopic Keratoconjunctivitis: Pharmacotherapy for the Elderly. Drugs Aging. 2019;36(7):581-8. doi: 10.1007/s40266-019-00676-7
Keywords
open-angle glaucoma
neovascular glaucoma
ocular hypertension
intraocular pressure